COMPANY
Ipsen
FDA-approved therapeutic company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Key Account Manager - North London & East Anglia | London (UK) | Oct 23, 2026 | Oct 23, 2026 |
| Manager Affaires Médicales Maladies Rares - CDD H/F | Paris | Oct 23, 2026 | Oct 23, 2026 |
| Directeur Affaires Médicales Maladies Rares H/F | Paris | Oct 23, 2026 | Oct 23, 2026 |
| Corporate Account Director - Pacific Northwest | 7 locations (listed on the posting) | Oct 22, 2026 | Oct 9, 2026 |
| Corporate Account Director - Great Lakes | 4 locations (listed on the posting) | Oct 22, 2026 | Oct 9, 2026 |
Trial and FDA signals
- New trial + clinical hiring Started a Phase 3 trial (NCT07779252, actual start Aug 25, 2026); 22 clinical-operations roles open. ClinicalTrials.gov NCT07779252 (Aug 25, 2026)
Evidence (1 event)
- Aug 25, 2026 · ClinicalTrials.gov NCT07779252
leadSponsor.name='Ipsen'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-25,type:ACTUAL}; studyFirstPostDate=2026-08-21; briefTitle='A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between '
- Aug 25, 2026 · ClinicalTrials.gov NCT07779252
Timeline
- Trial start Phase 2/Phase 3: A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Par source ↗
- Board tracked Radar started tracking this company’s job board (266 open jobs at last check). source ↗
- Trial start Phase 3: A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows source ↗
- Trial start —: Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy source ↗
- Trial start —: A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment source ↗
- Trial start —: Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies source ↗
- Trial start Phase 3: A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis source ↗
- Trial start —: Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC) source ↗
- Trial start —: A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China source ↗
- Trial start Phase 1: A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours source ↗
- Trial start Phase 3: A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows source ↗
- Trial start Phase 3: A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows source ↗
- Trial start Phase 1/Phase 2: A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid source ↗
- Trial start —: Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment source ↗
- Trial start —: A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in Spain source ↗
- Trial start Phase 1/Phase 2: A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tu source ↗
- Trial start —: A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea source ↗
- Trial start —: A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) source ↗
- Trial start Phase 2: A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults source ↗
- Trial start —: A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment source ↗
- Trial start Phase 1/Phase 2: A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours source ↗
- Trial start Phase 1: A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose source ↗
- Trial start Phase 3: A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) source ↗
- Trial start —: A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP) source ↗
- Trial start Phase 2: Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma source ↗
Upcoming milestones
- Nov 30, 2026 (ESTIMATED) · · Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC) · NCT07497724
- Dec 15, 2026 (ESTIMATED) · Phase 3 · A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows · NCT07435428
- Dec 15, 2026 (ESTIMATED) · Phase 3 · A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows · NCT07427797
- Dec 17, 2026 (ESTIMATED) · Phase 3 · A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) · NCT06730061
- Feb 28, 2027 (ESTIMATED) · · CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity · NCT06245772
- Mar 26, 2027 (ESTIMATED) · Phase 2 · A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults · NCT06937931
- Mar 31, 2027 (ESTIMATED) · · Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC) · NCT04106349
- Aug 19, 2027 (ESTIMATED) · Phase 1/Phase 2 · A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines · NCT04821089
Open jobs 266
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Key Account Manager - North London & East Anglia | London (UK) | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Manager Affaires Médicales Maladies Rares - CDD H/F | Paris | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Directeur Affaires Médicales Maladies Rares H/F | Paris | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Corporate Account Director - Pacific Northwest | 7 locations (listed on the posting) | Oct 22, 2026 | Oct 9, 2026 | Senior |
| Corporate Account Director - Great Lakes | 4 locations (listed on the posting) | Oct 22, 2026 | Oct 9, 2026 | Senior |
| Stagiaire CMC Regulatory Strategy | Paris | Oct 22, 2026 | Oct 20, 2026 | Not stated |
| Trainee, Asset Operations, Project Management (PM) Academy | Paris | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Senior Director, Global Clinical Development Lead – Rare Disease (Nephrology)” | 2 locations (listed on the posting) | Oct 21, 2026 | Oct 17, 2026 | Not stated |
| Key Account Manager, London and East of England | London (UK) | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| CDD - Chargé d’Études Senior – Développement Analytique H/F | Dreux | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Head of Finance Mexico | Mexico City | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Pharmacien Qualité Produit H/F | Signes | Oct 20, 2026 | Oct 20, 2026 | Not stated |
| Trainee Non Clinical Drug Safety – Starting January 2027 | Paris | Oct 20, 2026 | Oct 20, 2026 | Not stated |
| Senior Clinical Science Specialist, Rare Disease / Liver, West Palm Beach | 2 locations (listed on the posting) | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Senior Executive Assistant to the Chief Human Resources Officer (CHRO) | Paris | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Senior Clinical Development Scientist | Paris | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Early Development Asset Lead Oncology | 3 locations (listed on the posting) | Oct 19, 2026 | Oct 9, 2026 | Senior |
| Director, HCP Marketing, Bylvay | Cambridge (US) | Oct 19, 2026 | Oct 9, 2026 | Senior |
| Brand Manager | Seoul | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Cost & Value Management Analyst | 2 locations (listed on the posting) | Oct 16, 2026 | Oct 16, 2026 | Not stated |
| QA Technologist | Dublin | Oct 16, 2026 | Oct 16, 2026 | Not stated |
| Director Global Health Economics & Outcomes Research | 2 locations (listed on the posting) | Oct 16, 2026 | Oct 17, 2026 | Not stated |
| BD Strategy Operations & Excellence Lead | Paris | Oct 16, 2026 | Oct 17, 2026 | Not stated |
| Medical Science Liaison - Central Region (IL, IN, KY, TN, AL) | Berkeley Heights | Oct 15, 2026 | Oct 9, 2026 | Mid |
| Medical Science Liaison - Southeast Region (FL, GA, PR) | Berkeley Heights | Oct 15, 2026 | Oct 9, 2026 | Mid |
| Thought Leader Liaison, Rare Disease - West Region | 3 locations (listed on the posting) | Oct 15, 2026 | Oct 9, 2026 | Senior |
| Medical Advisor (Bangkok) | Bangkok | Oct 15, 2026 | Oct 15, 2026 | Entry |
| (Senior) Medical Science Liaison | Guangzhou | Oct 15, 2026 | Oct 15, 2026 | Mid |
| Global Marketing Director, Navtemadlin (Hematology/Oncology) | Cambridge (US) | Oct 15, 2026 | Oct 15, 2026 | Senior |
| Gerente de Ventas de Oncología y Neurología | Bogota | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Medical Event Project Manager | 2 locations (listed on the posting) | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Clinical Trial Administrator | Cambridge (US) | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Associate Director, Global Regulatory Affairs | Cambridge (US) | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Global Category Leader/ Responsable Catégorie Achats - Media Planning & Buying Services | 2 locations (listed on the posting) | Oct 14, 2026 | Oct 9, 2026 | Senior |
| Global Category Leader – Creative & Advertising / Responsable Catégorie Achats Création & Publicité | 2 locations (listed on the posting) | Oct 14, 2026 | Oct 9, 2026 | Senior |
| Training Manager DACH (w/m/d) | Munich | Oct 14, 2026 | Oct 14, 2026 | Mid |
| Medical Science Liaison | Seoul | Oct 14, 2026 | Oct 14, 2026 | Mid |
| Global Marketing Director, Iqirvo | Cambridge (US) | Oct 14, 2026 | Oct 15, 2026 | Senior |
| Business Process Lead | 3 locations (listed on the posting) | Oct 13, 2026 | Oct 9, 2026 | Senior |
| Sales Specialist, Central Taiwan | Taipei | Oct 13, 2026 | Oct 9, 2026 | Mid |
| Senior Manager, Global Late-Stage Partnering (Business Development) | Cambridge (US) | Oct 13, 2026 | Oct 14, 2026 | Senior |
| Country Manager, Ireland | Dublin | Oct 13, 2026 | Oct 14, 2026 | Mid |
| Alternant(e) Gestionnaire formation à partir de novembre 2026 H/F | Paris | Oct 13, 2026 | Oct 14, 2026 | Mid |
| Global Procurement Strategic Sourcing Director / Directeur Achats Sourcing Stratégique Global, Technology H/F | Paris | Oct 13, 2026 | Oct 14, 2026 | Senior |
| Legal Director Assets & Brands/ Directeur Juridique Actifs & Marques H/F (CDD 6 mois) | Paris | Oct 12, 2026 | Oct 12, 2026 | Senior |
| Stagiaire Pharmacovigilance et Infomed | Paris | Oct 12, 2026 | Oct 12, 2026 | Entry |
| Market Access Manager, SG & MY | 2 locations (listed on the posting) | Oct 12, 2026 | Oct 12, 2026 | Mid |
| Head of Growth Acceleration International | 2 locations (listed on the posting) | Oct 12, 2026 | Oct 14, 2026 | Executive |
| Lead of Growth Acceleration International | Paris | Oct 12, 2026 | Oct 14, 2026 | Senior |
| 高级医药代表-丽水/衢州 | Lishui | Oct 10, 2026 | Oct 10, 2026 | Mid |
Clinical trials (lead sponsor) Showing 50 of 288
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT03945773 | Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors | Phase 2 | Completed | Jan 8, 2020 | May 11, 2023 (actual) |
| NCT07556913 | Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy | Not listed | Recruiting | Jul 29, 2026 | Jan 31, 2039 (estimated) |
| NCT04821089 | A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines | Phase 1/Phase 2 | Active, not recruiting | Apr 6, 2021 | Aug 19, 2027 (estimated) |
| NCT06258902 | Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation | Not listed | Recruiting | Sep 28, 2023 | May 31, 2032 (estimated) |
| NCT07588880 | A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China | Not listed | Recruiting | Apr 16, 2026 | Apr 30, 2031 (estimated) |
| NCT07185919 | A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea | Not listed | Recruiting | Oct 30, 2025 | Sep 30, 2032 (estimated) |
| NCT06850038 | A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment | Not listed | Recruiting | Apr 22, 2025 | Nov 30, 2030 (estimated) |
| NCT06016842 | A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Phase 3 | Recruiting | Aug 31, 2023 | May 31, 2029 (estimated) |
| NCT07497724 | Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC) | Not listed | Active, not recruiting | Apr 26, 2026 | Nov 30, 2026 (estimated) |
| NCT07441707 | A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours | Phase 1 | Active, not recruiting | Mar 10, 2026 | Jul 31, 2030 (estimated) |
| NCT07387549 | A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis | Phase 3 | Recruiting | May 14, 2026 | Apr 30, 2031 (estimated) |
| NCT07213817 | A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours | Phase 1/Phase 2 | Recruiting | Dec 5, 2025 | Oct 30, 2028 (estimated) |
| NCT06447168 | A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment | Not listed | Active, not recruiting | Oct 14, 2024 | Jul 15, 2032 (estimated) |
| NCT06730061 | A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) | Phase 3 | Active, not recruiting | Jan 16, 2025 | Dec 17, 2026 (estimated) |
| NCT06089616 | A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP) | Not listed | Recruiting | Dec 5, 2024 | Dec 5, 2035 (estimated) |
| NCT07585097 | A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment | Not listed | Recruiting | Jul 10, 2026 | Sep 30, 2031 (estimated) |
| NCT07314164 | Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment | Not listed | Recruiting | Dec 17, 2025 | Oct 31, 2027 (estimated) |
| NCT05627362 | A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. | Phase 2 | Active, not recruiting | Dec 29, 2022 | Sep 23, 2031 (estimated) |
| NCT07435428 | A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows | Phase 3 | Active, not recruiting | Feb 18, 2026 | Dec 15, 2026 (estimated) |
| NCT06305247 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | Phase 1/Phase 2 | Active, not recruiting | Apr 3, 2024 | Mar 20, 2028 (estimated) |
| NCT04106349 | Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC) | Not listed | Active, not recruiting | Mar 3, 2020 | Mar 31, 2027 (estimated) |
| NCT03647878 | Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment. | Not listed | Active, not recruiting | Sep 24, 2018 | Sep 30, 2027 (estimated) |
| NCT06833008 | A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours | Phase 1/Phase 2 | Active, not recruiting | Mar 14, 2025 | Apr 4, 2028 (estimated) |
| NCT07779252 | A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows | Phase 3 | Recruiting | Aug 25, 2026 | Apr 10, 2028 (estimated) |
| NCT06245772 | CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity | Not listed | Active, not recruiting | Nov 16, 2023 | Feb 28, 2027 (estimated) |
| NCT07623187 | A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy | Phase 2/Phase 3 | Not yet recruiting | Nov 1, 2026 | May 31, 2031 (estimated) |
| NCT07427797 | A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows | Phase 3 | Active, not recruiting | Feb 27, 2026 | Dec 15, 2026 (estimated) |
| NCT06625060 | A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults | Phase 2 | Active, not recruiting | Oct 10, 2024 | Oct 31, 2027 (estimated) |
| NCT06937931 | A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults | Phase 2 | Recruiting | Jun 30, 2025 | Mar 26, 2027 (estimated) |
| NCT06055725 | A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development | Not listed | Active, not recruiting | Nov 1, 2023 | Nov 30, 2027 (estimated) |
| NCT06047444 | A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults | Phase 3 | Active, not recruiting | Oct 12, 2023 | May 28, 2026 (actual) |
| NCT06047457 | A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults | Phase 3 | Active, not recruiting | Sep 29, 2023 | Jun 1, 2026 (actual) |
| NCT07213830 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies | Phase 1/Phase 2 | Recruiting | Feb 6, 2026 | Jul 14, 2032 (estimated) |
| NCT04526665 | Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) | Phase 3 | Active, not recruiting | Sep 24, 2020 | Jun 1, 2023 (actual) |
| NCT07191704 | A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in Spain | Not listed | Completed | Dec 8, 2025 | Jun 3, 2026 (actual) |
| NCT04752774 | A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity. | Phase 1/Phase 2 | Recruiting | Apr 29, 2021 | Mar 30, 2029 (estimated) |
| NCT05377684 | Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment | Not listed | Completed | Jun 9, 2022 | Jun 4, 2026 (actual) |
| NCT04936542 | A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity. | Phase 4 | Completed | Jun 23, 2021 | Aug 26, 2025 (actual) |
| NCT06383403 | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. | Phase 3 | Completed | Jul 9, 2024 | Jun 16, 2026 (actual) |
| NCT05361434 | A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults | Not listed | Completed | Sep 26, 2022 | Oct 20, 2025 (actual) |
| NCT07049887 | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | Not listed | Completed | Jul 16, 2025 | Feb 23, 2026 (actual) |
| NCT06908954 | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | Phase 1 | Completed | Mar 14, 2025 | Feb 6, 2026 (actual) |
| NCT07282548 | Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies | Not listed | Withdrawn | 2026-06 | Jun 30, 2031 (estimated) |
| NCT04083235 | A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment | Phase 3 | Completed | Feb 11, 2020 | Jul 23, 2022 (actual) |
| NCT06341712 | Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma | Phase 2 | Terminated | Nov 22, 2024 | Feb 27, 2026 (actual) |
| NCT03516110 | Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy | Not listed | Completed | Mar 9, 2018 | Feb 28, 2020 (actual) |
| NCT05169775 | A Single Centre, Prospective, Observational Study to Assess the Use of the Rehabilitation Tool, GripAble, in Patients With Upper Limb Spasticity Receiving Botulinum Toxin-A (BoNT-A) in the United Kingdom (UK). | Not listed | Completed | Mar 2, 2022 | Jan 4, 2023 (actual) |
| NCT05590793 | Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate | Phase 3 | Completed | Nov 17, 2022 | Aug 20, 2024 (actual) |
| NCT05224349 | Effectiveness and Safety of SMART [Spastic Muscle Palpation by Anatomic Landscape for BoNT-A (Botulinumtoxin-A) Injection to Reduce Muscle Tone] BoNT-A Therapy With Dysport® in Patients With Post-stroke Chronic Upper Limb Spasticity (ULS) in Real-life Setting. | Not listed | Completed | May 9, 2022 | Apr 9, 2025 (actual) |
| NCT05458856 | Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate | Phase 3 | Completed | Aug 30, 2022 | Jul 8, 2024 (actual) |
Connect
See your connections at Ipsen on LinkedIn (search by name, results not checked)